SCHEMBL2483649

SCHEMBL2483649

Cc1cc(Nc2ncc(C#N)c(N)n2)ccc1N1CCN(C)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.63
FLT3 P36888 2/20 0.54
JAK2 O60674 3/20 0.52
JAK3 P52333 3/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
TNK2 Q07912 5/20 0.51
PKMYT1 Q99640 2/20 0.51
PAK1 Q13153 3/20 0.50
BRD4 O60885 1/20 0.50
AXL P30530 3/20 0.49
KDR P35968 2/20 0.47
CDC7 O00311 1/20 0.47
PLK4 O00444 1/20 0.47
CHEK1 O14757 1/20 0.47
AURKA O14965 1/20 0.47
DCLK1 O15075 1/20 0.47
PDPK1 O15530 1/20 0.47
DAPK3 O43293 1/20 0.47
ROCK2 O75116 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12224497 0.87 SLC2A1 (0.67) SLC2A1FLT3JAK2JAK3TNK2
SCHEMBL3955783 0.84 AXL (0.59) SLC2A1FLT3JAK2JAK3TNK2
SCHEMBL2479934 0.84 NPC1 (0.60) SLC2A1FLT3JAK2JAK3NPC1
SCHEMBL12197991 0.81 FLT3 (0.54) SLC2A1FLT3JAK2JAK3TNK2
SCHEMBL29531326 0.76 AXL (0.60) SLC2A1FLT3JAK2JAK3TNK2
SCHEMBL29576910 0.76 PAK1 (0.57) SLC2A1FLT3JAK2JAK3TNK2
SCHEMBL1811996 0.76 TNK2 (0.58) SLC2A1FLT3TNK2EGFRBTK
SCHEMBL2476657 0.75 TNK2 (0.55) SLC2A1FLT3JAK2JAK3TNK2
SCHEMBL19217986 0.74 JAK3 (0.62) SLC2A1FLT3JAK2JAK3TNK2
SCHEMBL30997623 0.74 WEE1 (0.57) SLC2A1FLT3JAK2JAK3TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376493-B1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE MSD KK (JP) 2016-10-05 EP disclosed
EP-2376493-B1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE MSD KK (JP) 2016-10-05 EP disclosed
US-8507505-B2 Dihydropyrazolopyrimidinone derivative MSD K.K. (JP) 2013-08-13 US disclosed
US-8507505-B2 Dihydropyrazolopyrimidinone derivative MSD K.K. (JP) 2013-08-13 US disclosed
EP-2376493-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE MSD K.K. (JP) 2011-10-19 EP disclosed
US-20110243891-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD K.K. 2011-10-06 US disclosed
US-20110243891-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD K.K. 2011-10-06 US disclosed
WO-2010067886-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-06-17 WO disclosed
WO-2010067886-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110243891-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE WEE2, WEE1, RPS6KA1 SLC2A1 2999/4885FLT3 416/4885JAK2 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.